Leprosy Cases are Rising
The word “leprosy” conjures images of biblical plagues, but the disease is still with us today here in the United ...
When Your Insurance Vanishes
Patients can change insurance only during end-of-year enrollment periods or at the time of “qualifying life events”.
Copay Assistance Backfires
Insurers or employers can tap into funds provided to patients by drugmakers through copay assistance programs.
Who Are We to Judge?
This is a constant feature of violence, where young and old alike are released after violent acts only to commit ...
How Medicare Advantage Plans Game the System
There has been concern about how these plans manipulate Medicare reimbursements by adjusting the coding density of the superbills.
Two Headed Monster Returns
The first “head” is the DEA Production Quotas. The second “head” is the 41 State Attorneys General’s nationwide opioid settlement.
Wrongful Prosecution of Dr. Richard Paulus
Fifteen years ago, an “anonymous” person contacted the federal authorities and said that Dr. Richard Paulus was committing fraud.
Health Startups: Manage Expectations
Whenever you work with or hire people, it is almost always a good idea to set and clarify expectations for ...
How to Regulate Healthcare When We Can’t Define it?
The regulation of healthcare is a complex and multifaceted issue that requires careful consideration of key procedures and conditions.
Semaglutide: Keeps Getting Better
Are all these benefits of semaglutide and tirzepatide legitimate or are the clinical studies exaggerating the benefits?
The Overdose Crisis Gets Worse
Opioid addiction doesn’t get as many headlines as it used to, but the crisis is as bad as ever. It ...
Tips to Inject Kindness in Medicine
By incorporating kindness into your clinical encounters, you can greatly enhance the overall patient experience.
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more